Opioid use disorder

Data Cubed Wins Semi-Finalist Spot for App Designed to Fight Opioid Addiction

Retrieved on: 
Tuesday, May 15, 2018
Substance dependence, Gaming, Gamification, Opioid use disorder, Opioid, Psychology

The ResQ app mobilizes an individual's social support network to intervene at times when the risk of relapse is greatest.

Key Points: 
  • The ResQ app mobilizes an individual's social support network to intervene at times when the risk of relapse is greatest.
  • It was one of five technology solutions selected by the Opioid Challenge, an innovation challenge intended to find technology-enabled tools to support and connect individuals affected by opioid addiction.
  • "Data Cubed's unique techniques of gamification in the collection and use of critical data can be a powerful tool.
  • Data Cubed, Inc. is a life-sciences tech company that is committed to building better societies through better data.

MINES & Associates' Cutting-Edge Opioid Complex Case Management Program

Retrieved on: 
Monday, May 14, 2018
Health, Healthcare quality, Substance dependence, Case management, Healthcare in the United States, Insurance in the United States, Aftercare, Managed care, Opioid use disorder, Opioid

DENVER, May 14, 2018 /PRNewswire/ --MINES& Associates (MINES), a nationally recognized business psychology firm, helps self-insured organizations with its innovative Opioid Complex Case Management Program aimed at improving treatment and reducing costs of opioid abuse treatment cases.

Key Points: 
  • DENVER, May 14, 2018 /PRNewswire/ --MINES& Associates (MINES), a nationally recognized business psychology firm, helps self-insured organizations with its innovative Opioid Complex Case Management Program aimed at improving treatment and reducing costs of opioid abuse treatment cases.
  • MINES has been at the forefront of managed care services, providing complex case management services that produce cost-effective care in the least restrictive settings.
  • MINES has saved its self-insured clients tens of millions of dollars while ensuring that the patient has received appropriate care.
  • MINES accomplishes this through an aggressive complex case management protocol designed to communicate directly with the patient and their family regarding costs, treatment, expectations for the facility regarding pre-certification, concurrent review, discharge planning, and long-term aftercare.

New regulations to provide better information for patients on the safe use of opioid medications

Retrieved on: 
Wednesday, May 2, 2018
Substance dependence, Morphine, RTT, Health, Opioid epidemic, Opioid, Chemistry, Medicine, Palliative care, Opioid use disorder, Pain management in children

OTTAWA, May 2, 2018 /CNW/ -Opioids are sometimes the only medications that can help patients manage serious pain.

Key Points: 
  • OTTAWA, May 2, 2018 /CNW/ -Opioids are sometimes the only medications that can help patients manage serious pain.
  • Health Canada wants to ensure that Canadian patients receive consistent, relevant information about the safe use of prescription opioids and their potential risks.
  • These new measures are part of actions that the Government of Canada is taking to help address the opioid crisis.
  • "Information is one of our most important tools for keeping ourselves and our families healthy and safe.

Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

Retrieved on: 
Monday, April 30, 2018
Chemistry, RTT, Morphinans, Medicine, Organic chemistry, Euphoriants, Substance dependence, Morphine, Opioid use disorder, Opioid, Drug overdose, Opioid epidemic

The data support the need for a multifaceted approach including abuse-deterrent opioids such as ARYMO ER to address the prescription opioid misuse and abuse crisis.

Key Points: 
  • The data support the need for a multifaceted approach including abuse-deterrent opioids such as ARYMO ER to address the prescription opioid misuse and abuse crisis.
  • "Data presented at AAPM examined the potential for ARYMO ER to help deter opioid abuse," said Colville Brown, MD, medical director at Egalet.
  • Abuse of ARYMO ER by injection, as well as by the oral and nasal routes, is still possible.
  • ARYMO ER exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.

Adapt Pharma® donates 20,000 doses of NARCAN® (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations

Retrieved on: 
Thursday, April 26, 2018
RTT, Chemistry, Medicine, Clinical medicine, Morphinans, Medical emergencies, Opioid antagonists, Alcohols, Naloxone, Opioid overdose, Opioid use disorder, Drug overdose

DUBLIN, April 26, 2018 /PRNewswire/ --Adapt Pharma (Adapt) ( adaptpharma.com ) welcomes the Surgeon General and National Council for Behavioral Health (National Council) for highlighting the need to make naloxone available to members nationwide that provide residential treatment for opioid use disorder.

Key Points: 
  • DUBLIN, April 26, 2018 /PRNewswire/ --Adapt Pharma (Adapt) ( adaptpharma.com ) welcomes the Surgeon General and National Council for Behavioral Health (National Council) for highlighting the need to make naloxone available to members nationwide that provide residential treatment for opioid use disorder.
  • NARCAN Nasal Spray 4mg is the first and only FDA-approved, needle-free formulation of naloxone for the emergency treatment of a known or suspected opioid overdose.
  • NARCAN Nasal Spray is not a substitute for emergency medical care, and additional doses of NARCAN Nasal Spray may be required until emergency medical assistance arrives.
  • Adapt Pharma is a privately-held company committed to expanding affordable access to NARCAN (naloxone HCl) Nasal Spray and to progressing treatment options in the field of addiction.

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to encourage more widespread innovation and development of new treatments for opioid use disorder

Retrieved on: 
Friday, April 20, 2018
Substance dependence, Health, Food and Drug Administration, United States Public Health Service, Chemistry, Opioid use disorder, Morphinans, Addiction, Organic chemistry, Opioid epidemic

The FDA remains committed to take steps across all of its authorities to make significant inroads against this tragic epidemic.

Key Points: 
  • The FDA remains committed to take steps across all of its authorities to make significant inroads against this tragic epidemic.
  • Along with our colleagues across the Department of Health and Human Services, the FDA is working to break the cycle of opioid addiction.
  • One of the critical ways the FDA can play a role is by encouraging more widespread innovation and development of medication for use in medication-assisted treatments (MAT).
  • These new guidance documents may ultimately lead to new treatments that improve outcomes for those struggling with an opioid addiction.

FDA takes new steps to advance the development of innovative products for treating opioid use disorder

Retrieved on: 
Friday, April 20, 2018
Morphinans, Cell signaling, Chemistry, Neurochemistry, Drug rehabilitation, RTT, Opioid antagonists, Ethers, Buprenorphine, Opioid use disorder, Opioid, Food and Drug Administration

"Today's action by FDA reflects the Trump Administration's commitment to bringing the best science we have to bear in the fight against opioid addiction.

Key Points: 
  • "Today's action by FDA reflects the Trump Administration's commitment to bringing the best science we have to bear in the fight against opioid addiction.
  • At proper doses, buprenorphine can also block the pleasurable effects of other opioids, making continued opioid abuse less attractive.
  • The FDA's draft guidance, "Opioid Dependence: Developing Buprenorphine Depot Products for Treatment," focuses on ways drug companies can more efficiently explore innovations in depot buprenorphine products.
  • The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

MedicFP Announces Partnership Agreement with CoreChoice to Provide Breakthrough, Patient-Centric Technology for Treating Opioid Addiction

Retrieved on: 
Thursday, April 19, 2018
Economy, Insurance industry, Substance dependence, Finance, Money, Opioid use disorder, Opioid, Insurance, Third-party administrator, Opioid epidemic

Under the terms of the partnership, MedicFP will provide state-of-the-art, mobile software solutions known as VerifyCare to an opioid treatment program targeted at CoreChoice clients in the group health, workers' compensation, and self-insured markets including unions and their members.

Key Points: 
  • Under the terms of the partnership, MedicFP will provide state-of-the-art, mobile software solutions known as VerifyCare to an opioid treatment program targeted at CoreChoice clients in the group health, workers' compensation, and self-insured markets including unions and their members.
  • The reports provide clinical care managers at opioid abuse treatment facilities with the information and assurance they need to develop multi-faceted opioid treatment plans tailored to each member's individual needs.
  • The program is the first of its kind to address the opioid abuse epidemic by providing breakthrough technology to patient-centered care.
  • Clients of CoreChoice include cost management companies, PPO groups, third party administrators (TPA), self-insured entities, employer group, and government organizations.

CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Help Combat Opioid Abuse

Retrieved on: 
Thursday, April 19, 2018
Chemistry, RTT, Medicine, Woonsocket, Rhode Island, Clinical medicine, Medical emergencies, Morphinans, Opioid antagonists, CVS Pharmacy, CVS Health, Naloxone, Opioid use disorder

The CVS Health Foundation will also provide an $85,000 grant to Cleveland's Neighborhood Family Practice, a network of community health centers, to support opioid addiction recovery.

Key Points: 
  • The CVS Health Foundation will also provide an $85,000 grant to Cleveland's Neighborhood Family Practice, a network of community health centers, to support opioid addiction recovery.
  • "CVS Health is dedicated to addressing and preventing opioid abuse and misuse in the communities we serve," said Thomas G. Davis, R.Ph., Vice President of Professional Services for CVS Health.
  • The 28 new medication disposal units that have been installed inside CVS Pharmacy locations in Ohio will supplement the 33 units CVS Health has previously donated to police departments across the state.
  • CVS Health has also worked to expand access to the opioid overdose-reversal drug naloxone in 46 states, including Ohio.